Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00631527 · ClinicalTrials.gov registry record · Phase 1
Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT00631527: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00631527 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00631527, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn the safety of adding 3 different dose-levels of Sutent® (sunitinib malate) to a combination of hormone therapy and radiation in patients with prostate cancer.
Interventions
- DRUG Goserelin
- RADIATION Radiation Therapy (RT)
- DRUG Leuprolide
- DRUG Sunitinib Malate
- DRUG Casodex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2008-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00631527
The ClinicalTrials.gov registry entry for NCT00631527 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Goserelin is the first listed.
NCT00631527 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00631527 about?
NCT00631527 is a clinical study titled "Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer". The goal of this clinical research study is to learn the safety of adding 3 different dose-levels of Sutent® (sunitinib malate) to a combination of hormone therapy and radiation in patients with prostate cancer.
What is the current status of trial NCT00631527?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2008-02.
What interventions are being tested in trial NCT00631527?
The interventions under investigation include: Goserelin (DRUG), Radiation Therapy (RT) (RADIATION), Leuprolide (DRUG), Sunitinib Malate (DRUG), Casodex (DRUG).
Who is sponsoring clinical trial NCT00631527?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.